We are a drug discovery bio-venture originated from Asahikawa Medical University, established based on the research of Professor Mikihiro Fujiya’s group, Division of Gastroenterology, Department of Internal Medicine, Asahikawa Medical University.

​

We were founded in April 2018 after inheriting research from Asahikawa Medical University and Sapporo Holdings Co., Ltd. on the "development of novel therapeutic agents for inflammatory bowel disease using probiotic-derived long-chain polyphosphoric acid".

​

​We are conducting research and development of candidate substances for new therapeutic agents utilizing probiotic-derived bioactive substances in the gastrointestinal and anticancer fields.